Menu
Close
.svg)
I've been hearing one word for months, and eventually I decided to find out why.
Every morning around six o'clock, I head downstairs to the NordicTrack treadmill in my basement. Like many people in our industry, I've turned that hour into an opportunity for professional continuing education. As I lace up my running shoes and put on my Beats earbuds, I usually let YouTube decide where my curiosity goes. More often than not, that means conversations hosted by Andrew Huberman, Steven Bartlett, Peter Attia, or other physicians and scientists discussing everything from metabolism and exercise to neuroscience and longevity.
Over the past several months, however, something unusual began happening. No matter where the conversation started, it seemed to arrive at the same destination.
Peptides.
Initially, I dismissed it as another healthcare buzzword. Every few years, a new scientific term captures the imagination of podcasters and social media before gradually disappearing into the background. But this felt different. Peptides weren't simply appearing in discussions about obesity or GLP-1 therapies. They were showing up in conversations about muscle recovery, inflammation, autoimmune disease, sleep, cognitive performance, healthy aging, and metabolic health. Then the topic began appearing somewhere else entirely: STAT+, Endpoints News, MM+M, Harvard Medical School, and (just last week) a steady stream of FDA coverage surrounding advisory committee meetings on experimental peptide therapies.
By that point, it no longer felt like a coincidence. It felt like the early stages of something much larger. It also occurred to me that many commercial leaders were probably asking the same question I was.
Why is everyone suddenly talking about peptides?
One reason the current conversation can be confusing is that peptides are simultaneously old and new.
They are hardly an emerging scientific discovery. Some of the most important medicines in modern history are peptides. Perhaps the most well-known example, insulin, transformed the treatment of diabetes more than a century ago. More recently, GLP-1 receptor agonists such as semaglutide and tirzepatide have fundamentally reshaped the treatment of obesity and metabolic disease. Calcitonin, oxytocin, and parathyroid hormone analogs have all been established components of modern medicine for years.
What's new is not peptides themselves. What's new is our growing ability to design them.
Peptides are simply short chains of amino acids -- the building blocks of proteins -- but their biological effects can be remarkably precise. Because they interact with highly specific receptors and signaling pathways, researchers increasingly view them as programmable biological messengers capable of influencing inflammation, metabolism, tissue repair, endocrine function, immune activity, and neurological signaling.
Advances in computational biology, protein engineering, medicinal chemistry, and drug delivery have dramatically expanded what scientists believe peptides may be capable of doing. In many respects, peptides are evolving from individual medicines into a scientific platform.
That distinction is relevant.
The pharmaceutical industry has seen this story before. Monoclonal antibodies were once viewed as highly specialized therapies before becoming foundational across oncology, immunology, and inflammatory disease. RNA therapeutics, antibody-drug conjugates, and cell therapies followed similar trajectories. Each began as a scientific breakthrough before becoming an entire category of innovation.
It increasingly seems as though peptides may be entering that same conversation.
The recent FDA discussions illustrate just how broad the field has become. Unlike earlier generations of peptide medicines, the compounds now attracting attention are aimed at an exceptionally wide range of biological processes.
Whether these individual compounds ultimately prove safe and effective remains an open scientific question. Many have limited human clinical evidence, which explains why FDA reviewers have urged caution even as patients, HCPs, and compounding pharmacists argue for broader access. But stepping back from the regulatory debate reveals something much more interesting.
The field itself is expanding rapidly.
Researchers are no longer asking whether peptides can treat one disease. They're asking whether carefully engineered peptides can influence an entire spectrum of biological systems. Repair. Inflammation. Metabolism. Neurology. Endocrinology. Healthy aging.
That breadth is what I took note of. Individual drug candidates succeed or fail every day. Entire scientific platforms emerge much less frequently.
One thing that makes the peptide story particularly fascinating, however, isn't simply the science. It's how the conversation spread.
Historically, pharmaceutical innovation followed a remarkably orderly journey. A discovery emerged from an academic laboratory or an early-stage biotech company. Clinical studies across multiple phases of development were presented at scientific meetings and published in medical journals. Pharmaceutical companies continued to invest in that development while promoting early awareness. Physicians gradually adopted the science. Eventually, patients became aware of the new therapy.
Peptides seem to be following a different trajectory.
Long before many physicians became familiar with names like BPC-157 or TB-500, they had become regular topics on YouTube, Reddit, longevity clinics, and podcasts hosted by Joe Rogan, Andrew Huberman, Peter Attia, Steven Bartlett, and others. Consumers weren't waiting for pharmaceutical companies to introduce these compounds. They were discovering them themselves, comparing protocols online, discussing personal experiences, and arriving in physicians' offices asking questions about therapies that many clinicians were only beginning to investigate.
That reversal is remarkable.
For perhaps the first time, a major area of therapeutic innovation has entered public consciousness through digital communities rather than through traditional medical channels.
The recent FDA advisory committee meetings are, in many ways, emblematic of that shift. Regulators are no longer responding solely to scientific discovery. They are responding to consumer demand that has already become widespread, even while many of the underlying scientific questions remain unanswered.
Whether that proves to be beneficial or problematic is a debate that will continue for years. But the change itself is undeniable.
For those of us working across the different functions in pharma, I suspect the peptide story is about far more than peptides. It represents a new model for how medical innovation becomes a reality.
The pharmaceutical industry has traditionally excelled at translating science for physicians and patients. These days, however, consumers are encountering emerging therapies long before pharmaceutical companies ever have the opportunity to shape the conversation. Podcasts, online communities, longevity clinics, and digital influencers are introducing millions of people to scientific concepts that have yet to become part of routine clinical practice.
That has profound implications.
Market research can no longer focus exclusively on physicians. Medical affairs can no longer assume scientific meetings are where awareness begins. Commercial organizations can no longer afford to treat podcasts, YouTube, Reddit, and other digital communities as outside the mainstream of market intelligence. Increasingly, these are becoming the most early indicators of patient expectations, emerging demand, and future commercial opportunities.
In many ways, peptides are teaching us to look in different places.
Whether peptides ultimately become one of the defining therapeutic platforms of the next decade remains to be seen. Drug development has always been an exercise in parsing out true breakthroughs from promising ideas that never fulfill their early expectations. Many of today's most discussed peptides may ultimately fail rigorous clinical testing - or worse, they might prove to be fundamentally unsafe. Some perhaps may become important medicines. A few might even be transformative. We simply don't know yet.
What we do know is something else. The route by which scientific ideas enter public consciousness has changed.
The peptide phenomenon suggests that tomorrow's important therapeutic trends may first emerge not in the pages of The New England Journal of Medicine, but in podcast interviews, online communities, and digital conversations that capture public imagination long before scientific consensus has fully formed.
That should challenge all of us.
The scientific verdict on many of today's experimental peptides remains years away. The commercial implications, however, are already here. Consumers are discovering emerging therapies earlier than ever before, physicians are increasingly responding to questions that originate outside the clinic, and pharmaceutical companies are entering conversations they no longer fully control. Peptides may or may not become one of the defining therapeutic platforms of the next decade. But they have already become an instructive case study in how innovation reaches the world.
